The CSL (ASX:CSL) share price is up just 3% so far in 2021. Here's why

The company's shares have been on a rollercoaster ride…

| More on:
A male doctor wearing a white doctor's coat shrugs and holds his hands up to indicate the unimpressive CSL share price as a result of OOVID-19

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The CSL Limited (ASX: CSL) share price has been a hot topic over the course of the year. The company has been severely challenged by COVID-19 restrictions and this has had a profound impact on its share price.

The greatest impact has been a dramatic decline in plasma donations in the United States during the crisis.

The global biotech's shares closed Thursday's session at $294.65 apiece, down 1.02%.

What has CSL announced lately?

While CSL hasn't reported any price-sensitive news since its full-year results, it did release its R&D investor briefing on Tuesday.

The company highlighted that it spent more than US$1 billion on R&D activities in the past financial year. This consisted of new product development, market development, and life cycle management products.

A number of therapeutics were approved for use across Japan, the United States, Europe, Russia, and Mexico. Most of these products came from CSL's immunology and haematology portfolio.

In its FY21 results, CSL reported that the immunology division made US$4,238 million (A$5,648 million), which was almost half of its total revenue of US$8,547 million (A$11,391 million). Treatments for haemophilia accounted for US$1,107 million (A$1,475 million) for the year.

In addition, the company is building a new cell culture facility in Tullamarine, Victoria. Scheduled to open in 2026, the plant will produce the next-generation cell-based seasonal influenza vaccines.

CSL has an $800 million 10-year supply agreement with the Commonwealth Government for antivenoms, Q-fever vaccines and pandemic influenza vaccines.

Two broker notes came in yesterday, both raising their outlook on the CSL share price.

The first from Jefferies revealed a bullish assessment with the 12-month price target lifted by 3.1% to $338. Leading global investment firm Goldman Sachs also improved its rating on CSL shares by 1% to $305.

How is CSL comparing against the ASX 200?

The S&P/ASX 200 Index (ASX: XJO) has returned 10.9% to shareholders in 2021 compared to CSL's 3.4%.

However, when looking at a longer timeframe, this is where things start to turn.

The benchmark index has risen by an average of 6.38% per year over the past 5 years and 5.99% per year over a 10-year period. CSL, on the other hand, has surged with a yearly average of 22.98% and 25.69% respectively.

CSL share price snapshot

Since the pandemic began, CSL shares have been on a rollercoaster ride and are down about 12% since February 2020.

CSL has been hampered by the slow recovery from COVID-19, affecting the company's business operations both domestically and internationally.

On valuation grounds, CSL is the second-largest company on the ASX with a market capitalisation of roughly $134.68 billion.

Motley Fool contributor Aaron Teboneras owns shares of CSL Ltd. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of and has recommended CSL Ltd. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

a biomedical researcher sits at his desk with his hand on his chin, thinking and giving a small smile with a microscope next to him and an array of test tubes and beackers behind him on shelves in a well-lit bright office.
Healthcare Shares

Broker says this ASX 200 biotech stock is a top buy

Let's see what Bell Potter is saying about this biotech.

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

Why CSL shares are a buy today despite the looming Trump tariffs

A leading expert believes CSL shares are still trading for a bargain today. Here's why.

Read more »

A businesswoman pulls her glasses down in shock to look at the bad news on her computer.
Healthcare Shares

Why did the Telix share price just crash 16%?

Investors are sending the Telix share price plunging today. But why?

Read more »

Broker analysing the share price.
Healthcare Shares

Expert: 2 ASX healthcare stocks to avoid before reporting season

Not all healthcare stocks are created equal.

Read more »

A group of people in a corporate setting do a collective high five.
Healthcare Shares

Should I buy Pro Medicus or CSL shares ahead of earnings season?

The ASX healthcare sector may be currently undervalued.

Read more »

Overjoyed man celebrating success with yes gesture after getting some good news on mobile.
Healthcare Shares

Why Mesoblast shares can keep storming higher

More big returns could be on the way for buyers of this high risk stock according to Bell Potter.

Read more »

Doctor doing a telemedicine using laptop at a medical clinic
Healthcare Shares

The Mesoblast share price just rocketed 38%! Here's why

ASX investors just sent the Mesoblast share price up 38%. But why?

Read more »

couple having a happy discussion with a banker
Healthcare Shares

Expert: 4 ASX healthcare stocks to buy ahead of reporting season

Could these ASX healthcare stocks be good additions to your portfolio?

Read more »